Biosafety aspects of the recombinant live oral Vibrio cholerae vaccine strain CVD 103-HgR.
The development of live attenuated vaccines, allowing for the safe and effective immunisation at mucosal surfaces, is a strategy of great interest for vaccinologists. The main advantage of this approach over conventional parenteral vaccines is the induction of strong mucosal immune responses, allowing targeting of the pathogen at the initial point of contact with the host. Further advantages include the ease of administration, high acceptance by vaccines, and relatively low production costs. Finally, well-characterised, safe and immunogenic vaccine strains are well suited as vectors for the mucosal delivery of foreign vaccine antigens and of DNA vaccines. However, such vaccines, when based on or containing genetically modified organisms (GMOs), are facing new and specific regulatory hurdles, particularly regarding the potential risks for humans and the environment. In this contribution we address selected aspects of the risk assessment of live attenuated bacterial vaccines covered in the course of the registration of vaccine strain CVD 103-HgR as a recombinant live oral vaccine against cholera.
Viret
Jean-François
JF
Berna Biotech Ltd., Rehhagstrasse 79, CH-3018 Berne, Switzerland. jf.viret@bernabiotech.com
Dietrich
Guido
G
Favre
Didier
D
D000284:Administration, Oral; D002771:Cholera / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000145:classification / Q000235:genetics / Q000276:immunology; D018014:Gene Transfer Techniques; D012449:Safety; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects* / Q000145:classification / Q000276:immunology; D014614:Vaccines, Synthetic / Q000008:administration & dosage*; D014734:Vibrio cholerae / Q000276:immunology*
D022121:Cholera Vaccines; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic